ERTEK, SIBEL
 Distribuzione geografica
Continente #
NA - Nord America 178
AS - Asia 91
EU - Europa 73
AF - Africa 9
SA - Sud America 5
Totale 356
Nazione #
US - Stati Uniti d'America 178
CN - Cina 33
SG - Singapore 31
GB - Regno Unito 29
DE - Germania 12
HK - Hong Kong 9
IN - India 8
CI - Costa d'Avorio 6
IT - Italia 6
RU - Federazione Russa 5
SE - Svezia 5
VN - Vietnam 5
BR - Brasile 4
UA - Ucraina 4
EE - Estonia 3
FR - Francia 3
ID - Indonesia 3
IE - Irlanda 3
ZA - Sudafrica 3
JO - Giordania 2
CH - Svizzera 1
CO - Colombia 1
FI - Finlandia 1
PL - Polonia 1
Totale 356
Città #
Southend 27
Wilmington 22
Fairfield 19
Singapore 19
Seattle 14
Ashburn 13
Houston 13
Santa Clara 13
Hong Kong 9
Woodbridge 9
Chandler 8
Ann Arbor 7
Abidjan 6
Princeton 6
Beijing 4
Jinan 4
Boardman 3
Bremen 3
Dublin 3
Nanjing 3
Padova 3
Semarang 3
Westminster 3
Amman 2
Cambridge 2
Dearborn 2
Falls Church 2
Hebei 2
Ho Chi Minh City 2
Jiaxing 2
Los Angeles 2
Nanchang 2
San Diego 2
Shanghai 2
Zhengzhou 2
Anicuns 1
Biên Hòa 1
Bologna 1
Buffalo 1
Chennai 1
Dallas 1
Fortaleza 1
Frankfurt Am Main 1
Fuzhou 1
Hangzhou 1
Hanoi 1
Helsinki 1
João Pessoa 1
Ninh Bình 1
Norwalk 1
Olalla 1
Pitalito 1
Pittsburgh 1
Pune 1
Redondo Beach 1
Saint Petersburg 1
Shenyang 1
Stockholm 1
Suzhou 1
Taboão da Serra 1
Taizhou 1
Warsaw 1
Wenzhou 1
Totale 266
Nome #
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. 129
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data 119
Nutraceuticals for metabolic syndrome management: from laboratory to benchside. 111
Totale 359
Categoria #
all - tutte 1.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.052


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 6 0 0 3
2021/202247 3 0 3 3 4 2 0 6 0 0 13 13
2022/202347 3 3 1 5 3 3 4 3 14 2 3 3
2023/202415 4 3 0 0 1 0 0 0 1 2 4 0
2024/202547 0 7 4 6 15 1 1 1 0 0 0 12
2025/202655 5 6 12 2 21 8 1 0 0 0 0 0
Totale 359